Bio-Rad launches validated antibodies for counting rare cells and circulating tumor cells

Bio-Rad launches validated antibodies for counting rare cells and circulating tumor cells

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of validated antibodies for rare cell and circulating tumor cell (CTC) enumeration. Validated for use with Bio-Rad's Celselect Slides Enumeration Stain Kits, the antibodies are specific for CTC surface markers to enable sensitive and specific identification of target cell populations, improving the study of tumor heterogeneity and disease progression at different stages.

Bio-Rad's Genesis Cell Isolation System is a customizable benchtop solution that utilizes unbiased, size-based cell selection to gently and efficiently capture a broad range of CTCs and other rare cells from liquid biopsy samples. Once captured, the enriched cells can be recovered for subsequent analysis or immunostained for immunofluorescence applications such as counting and identifying different CTC types on the slide.

Counting captured CTCs provides valuable insights into the surface markers that indicate cancer type and progression and is crucial for understanding the mechanisms of cancer metastasis. For successful counting, the antibody reagents must be carefully selected to ensure not only sensitivity and specificity to the target cell surface marker, but also compatibility with the staining method. Bio-Rad's new line of validated primary and secondary antibodies enables accurate immunostaining of captured CTCs, supporting cancer researchers working in this area.

"CTC analysis is a promising tool to study tumor heterogeneity and disease progression, providing real-time data and unique insights into cancer metastasis," said Stephen Kulisch, vice president of marketing for Bio-Rad's Digital Biology Group. "The introduction of validated antibodies to identify target cells reflects Bio-Rad's growing product portfolio in single-cell oncology and is a testament to our commitment to providing cancer researchers with highly efficient rare capture, enrichment, enumeration and recovery Cells to offer.”

To learn more about the new validated antibodies, visit bio-rad-antibodies.com/val-abs.

BIO-RAD and CELSELECT SLIDES are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions.

Sources: